Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835079 | 1.00 | NR3C1 (0.63) | NR3C1PGR | |
| SCHEMBL835078 | 1.00 | NR3C1 (0.63) | NR3C1PGR | |
| SCHEMBL3811632 | 0.92 | NR3C1 (0.63) | NR3C1PGR | |
| SCHEMBL836709 | 0.92 | NR3C1 (0.63) | NR3C1PGR | |
| SCHEMBL836710 | 0.92 | NR3C1 (0.63) | NR3C1PGR | |
| SCHEMBL835112 | 0.91 | NR3C1 (0.63) | NR3C1PGR | |
| SCHEMBL835111 | 0.91 | NR3C1 (0.63) | NR3C1PGR | |
| SCHEMBL836609 | 0.89 | NR3C1 (0.58) | NR3C1PGR | |
| SCHEMBL851198 | 0.89 | NR3C1 (0.58) | NR3C1PGR | |
| SCHEMBL3806415 | 0.89 | NR3C1 (0.58) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | claimed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | claimed |
| WO-2009142568-A1 | COMBINATION OF (A) GLUCOCORTICOID RECEPTOR MODULATOR AND (B) A B2-AGONIST | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009142589-A1 | COMBINATION OF (A) GLUCOCORTICOID RECEPTOR MODULATOR AND (B) A MUSCARINIC ANTAGONIST | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | disclosed |